trametinib

Details

Files

Generic Name:

trametinib

Project Status:

Active

Therapeutic Area:

Gynecological cancers

Manufacturer:

N/A

Call for patient/clinician input open:

September 12, 2024

Brand Name:

N/A

Project Line:

Reimbursement Review

Project Number:

PX0372-000

Call for patient/clinician input closed:

November 4, 2024

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

N/A

Submission Type:

Non-sponsored Submission

Fee Schedule:

Pending

Indications:

For recurrent low-grade serous ovarian cancer

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones²
Milestones title	Date
Submission received	September 06, 2024
Review initiated	September 09, 2024
Expert committee meeting (initial)	January 30, 2025

Last Updated : September 16, 2024